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CHAPTER 1: INTRODUCTION 
 The kidneys, located in the posterior wall of the body, perform many functions that the 
body relies upon to survive.  Such processes include waste excretion, chemical balance (e.g. 
electrolyte and acid-base balance, Calcium-Phosphate metabolism), regulation of blood pressure, 
in addition to fluid balance [44].  The kidneys’ complex structure contains a plethora of tissue 
layers and permeable membranes and vessels in a way where filtration, absorption, and secretion 
are some of the main objectives the kidneys are used for.  Blood circulation through the kidneys 
as well as excretion of waste products from it through urine is essentially the paths that allow for 
the aforementioned functions to occur [44].  The anatomy of the kidneys (figure 1.0) include 
complex parts such as the nephrons and glomerulus within the cortex, as well as the medulla, 
pyramid, pelvis, and ureter that allows waste-carrying urine to flow on to the bladder to be 
excreted from the body [44].  The nephrons provide the structural and functional units of the 
kidneys where the aforementioned processes allow urine formation to occur [44].  Any 
disruption or abnormalities in any of these processes can show signs of damage or failure to the 
kidneys [44]. 
 The circulation of blood flow through the kidneys is where the reabsorption, secretion, 
and excretion occurs [44].  Since these steps take place within the nephron via afferent and 
efferent arterioles, reabsorption of certain products (e.g. water, salts, sugars) can return to 
circulation within the body [44].  Secretion can occur to return certain components such as acids, 
minerals, urea, and byproducts of drugs in order to return to the renal tubule to be excreted in 
urine while other components reach circulation via the veins [44].  The glomerular capillaries are 
porous, allowing fluids that contain those byproducts mentioned previously (and proteins if there 
are underlying issues) [44].  The Bowman’s Capsule that contains the glomeruli, essentially 
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carrying the glomerular filtrate, occurs at a rate (glomerular filtration rate) affected by blood 
pressure [44].  Membranes inside the capsule filters the entering plasma so that certain molecules 
such as water and solutes can pass through, whereas, larger molecules like proteins could 
problematic and cause for concern [44].  Surface area available for filtration is adjustable due to 
blood pressure changes [44].  Normal GFR is designated between 120-125 mL/min in normal, 
adult kidneys, and rates below that range could be problematic considering normal amounts of 
filtrate are not being processed [44]. 
 Filtration in the remaining renal tubules (e.g. proximal, loop of Henle, distal) is 
responsible for secreting and reabsorbing certain contents in order to maintain a chemical 
balance within the blood affected by blood pressure [44].  This entails the reabsorption of 
molecules such as sodium ions, hydrogen ions, phosphates, bicarbonate, and water, as well as the 
secretion of urea, ammonia, and other toxic substances to be excreted in urine [44].  These two 
features allow the kidneys to help maintain fluid balance, electrolyte balance, control blood pH, 
eliminate nitrogenous wastes, as well as disposal of certain drugs and metabolites [44].  Keeping 
blood pH intact is necessary considering environmental conditions due to pre-existing conditions 
(e.g. diabetes, severe chloride depletion, lactic acid buildup) can either severely raise or lower 
those levels resulting in acidosis (low pH) and alkalosis (high pH) [44].  Waste management is 
especially important considering buildup of substances, such as urea, can affect kidney function 
in terms of a negative impact on GFR [44], [12]. 
 Kidney failure is a progressive and debilitating disease that affects many Americans.  
Numerous factors negatively affect the kidneys’ ability to function as they work to filter 
byproducts of multiple origins (e.g. metabolic wastes, drugs, fluid balance).  The repeated abuses 
often overload the kidneys, reduce their efficacy, and may result in their failure altogether [1].  
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Certain conditions such as metabolic syndrome, hypertension, and diabetes, are recurrent with 
chronic kidney disease (CKD) with the latter being the most prevalent of causative factors [2].  
Over time, the kidneys can stop functioning during CKD which can eventually lead to what is 
known as end stage renal disease (ESRD) [1].  Prevalence of ESRD has risen in the United States 
from 1980 until 2010. The adjusted rate of these prevalent cases has risen in 2010 to 1,763 per 
million populations, up 21 percent higher than 10 years prior (Figure 1.1).  
Among the ESRD population, approximately 400,000 people within that group are 
seeking dialysis treatment, including 33% that are African American [2]. ESRD continues to be 
the highest for African Americans compared to other ethnicities [2], [3].  However, between 
mortality and survivability, certain factors show the African American dialysis patients have a 
greater survival rate than whites (e.g. body mass, lipid profiles) [2].   
CKD is characterized by a decrease in kidney function over a given period of time [1].  
The rate at which blood flows into the kidneys must be determined using the Modification of 
Diet in Renal Disease (MDRD) formula [4] resulting in assigning a numerical value.  Again, this 
rate is known as the glomerular filtration rate (GFR), the rate at which blood flows into the 
vessels of the kidneys (glomeruli) through filters so that byproducts are separated and excreted 
out through urine [1]. The GFR levels (between 15 and 90 mL/min/1.72m2) that define the stages 
of CKD are also seen in Figure 1.2 [5]. ESRD occurs after stage 5, when there is an irreversible 
loss of function and renal replacement therapy is required [1].  As this is examined further, 
reabsorption and secretion steps involving the filtrate through the glomeruli and tubules can 
drastically reduce or not occur at all due to failed kidneys [44].  Eventually, the inability to form 
urine would be a clear indication of problematic situation among the kidneys where waste 
products cannot be eliminated which are returned to the blood [44].  The overlaying effect would 
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contribute to a negative impact on homeostasis involving factors such as electrolyte balance, 
blood pH, and fluid balance, as aforementioned. 
Aside from kidney transplantation, alternative forms of treatment modalities are 
peritoneal dialysis and hemodialysis.  With peritoneal dialysis, the use of blood vessels in the 
abdominal lining, or peritoneum, fills in the kidneys aided by a dialysate [4].  This dialysate is 
essentially a cleansing fluid that aids in the filtration of waste products as fluid passes through 
the peritoneal space [4] that is delivered via a surgically implanted catheter inside the abdomen.  
Hemodialysis requires the use of a dialysis machine that functions as an artificial kidney, or 
dialyzer, to filter the metabolic waste products, salts, and fluids from the blood [6].  This requires 
access to the blood vessels by way of a minor surgical procedure via the patients arm in what 
appears to be two incisions: one for removal and cleansing of the blood and the other to return 
the cleaned blood back into the patient’s system [4], [6].   
Based on current research, causes of CKD and ESRD stem from multiple factors: drug 
use, hypertension, and diabetes.  Drug use can lead to nephrotoxic effects on intra-glomerular 
blood flow, cell injury via cytotoxicity, and crystal induced obstruction of the vessels [7].  
During hypertension, high blood pressure forces the heart to work harder over time, thereby 
damaging blood vessels throughout the body, including blood vessels within the kidneys [8].  
Those inflicted with diabetes have higher levels of blood sugar that causes the kidney filters to 
become overloaded due to the extra work, eventually failing [8].  Early signs of diabetes induced 
kidney failure is detected when protein is found in urine [8]. 
 ESRD has an impact on morbidity and mortality of the patients as evidenced by 
increasing risk of hospitalizations and long term complications, including cardiovascular disease, 
malnutrition, and chronic inflammation [9].  The risk for cardiac events in the ESRD population 
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that receive treatment is approximately 3.5 to 50 times higher than the general population [9].  
The determinants of cardiovascular disease in this population include family history, 
hypertension, diabetes mellitus, dyslipidemia, and obesity [9].   
Co-morbidities lead to an increased mortality risk in the general population, though the 
effects of these conditions react differently for those on chronic hemodialysis.  Ikizler et al. noted 
that traditional risk factors towards mortality in the ESRD population appear to be disregarded 
when compared to the normal, healthy population. For example, low serum cholesterol usually 
associated with decreased risk of mortality in the general population is shown to be associated 
with higher rates of cardiovascular morbidity in the ESRD population [9].   High body mass 
synonymous with increased mortality in the general population has been shown to be protective 
in the ESRD population [9].  Researchers have been forced to explore nontraditional risk factors 
attributing to morbidity within the ESRD population.  These factors which include anemia, 
disturbance in mineral metabolism, oxidative stress, chronic inflammation, and uremic 
malnutrition [9].  Chronic inflammation, oxidative stress, and malnutrition are especially 
important in the clinical outcomes of the ESRD population [9] since they can affect body 
composition.  Interestingly, oxidative stress can increase inflammation within the body, which is 
caused by a buildup of toxins and decreased antioxidant intake stemming from malnutrition [9].  
Inflammation can cause an increase in resting energy expenditure (REE) [10].  Gradually the 
body is forced to rely on its own protein stores to attenuate the energy deficit (net protein 
catabolism), thereby causing a breakdown of muscle/lean body mass [9], [11] (Figure 1.4). Since 
the body has low energy intake and increased energy expenditure, it would rely on its own stores 
to make up that deficit which forces the body to waste away, resulting in a net protein catabolic 
state known as Protein Energy Wasting (PEW) [10].   
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The process of inflammation has been found to be associated with vascular disease in the 
general and dialysis populations [12], [13].  It had been found that specific cytokines such as 
interleukins are known to induce anorexia or a decrease/suppression in appetite [9], [12].  Toxins 
such as advanced glycation end products (AGE), that result from glycation reactions during 
glomerular filtration, builds up and therefore lowers defenses against oxidative injury [12].  
These AGE also activate mononuclear cells such as lymphocytes that triggers an inflammatory 
response [12], also inducing appetite suppression.  It is possible appetite suppression occurs by a 
decrease in the hormones, leptin and ghrelin [11], that are responsible for controlling the 
patient’s appetite. As a consequence, a decreased intake of energy and nutrients (including 
antioxidants) results [12], [13].  Cytokine and toxin buildup, coupled with a decrease in 
antioxidant intake, resulting in oxidative stress which further increases inflammation within the 
body [9].  
Other sources of inflammation emanate from dialytic factors.  Back filtration allows 
molecules such as endotoxins transported via dialysis fluid to end up in the blood due to high-
flux dialyzers [14].  This triggers an immune response.  Bio-incompatibility of dialysis 
membranes increases inflammatory factors within the dialysis patients through activation of 
mononuclear cells and white blood cells which are both adaptive responses the body has during 
an immune reaction, in addition to the activation of acute-phase responses (e.g. stimulation of 
cytokines, interleukins) [12].   
Co-morbid conditions induce inflammation in ESRD patients. Infections are common 
among hemodialysis patients because they pose a risk due to impaired immunity or vascular 
access [12].  Sources of infections stem from septicemia in diabetic patients due to low albumin 
levels, imperfection among dialysis grafts, and overlooked skin lesions due to diabetic 
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neuropathy of all which trigger an immune response [12] thereby increasing the rate of 
inflammation within the body[12], [13].  Moreover, uncontrolled blood glucose can give rise to 
non-enzymatic reactions of proteins (during the increase of AGE products) [12] can also trigger 
an immune response.  During CVD, pro inflammatory cytokines are highly associated with this 
and can further increase oxidative stress in addition to inflammation within the body [12], [15].  
Malnutrition is common in cases of CKD. Several researchers have reported on the 
prevalence of wasting among patients who have ESRD, especially those on hemodialysis [11].  
Conversely, uremia is characterized by a buildup of waste products within the bloodstream [4].  
Based on previous findings, this buildup of waste products stemming from ESRD complications 
is one of the main causative factors that primarily contribute to (uremic) malnutrition since it can 
affect nutrient intake due to inflammation. This wasting phenomenon had been defined as a 
consequence due to insufficiency of food intake with an increase in energy expenditure, resulting 
in a negative energy balance which ultimately causes the body to waste away [11].     
  CVD is a clinical outcome that is common in ESRD patients due to the increase in 
mortality risk [15].  The ESRD patients are also at risk for hospitalization due to poor nutritional 
status and inflammation stemming from dialysis and co-morbid related issues [15].  Malnutrition 
and inflammation play a role in mortality since they impact nutritional and inflammatory 
markers that link CVD with ESRD.  This may suggest that ESRD patients should be encouraged 
to control aforementioned complications in order to sustain health maintenance. 
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Figure 1.0: (a) Kidney anatomy; (b) Path of blood flow through renal blood vessels; 
(c) Three major renal processes within the nephron	  
	  
	  
(a)      (b) 
 
 
(c) 
 
[Adapted from http://www.interactive-biology.com/3254/the-anatomy-of-the-kidney and Marieb Human 
Anatomy and Physiology, 9th Edition, 2012] 
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 Tubular secretion. Tubular secretion (“selectively adding 
to the waste container”) is the process of selectively mov-
ing substances from the blood into the filtrate. Like tubular 
reabsorption, it occurs along he length of the tubule and 
collecting duct.
The kidneys process an enormous volume of blood each day. 
Of the approximately 1200 ml of blood that passes through the 
glomeruli each minute, some 650 ml is plasma, and about one-
fifth of this (120–125 ml) is forced into the glomerular capsules 
as filtrate. This is equivalent to filtering your entire plasma vol-
ume more than 60 times each day! Considering the magnitude 
of their task, it is not surprising that the kidneys (which account 
for only 1% of body weight) consume 20–25% of all oxygen 
used by the body at rest.
Filtrate and urine are quite different. Filtrate contains every-
thing found in blood plasma except proteins. Urine contains 
unneeded substances such as excess salts and metabolic wastes. 
The kidneys process about 180 L (47 gallons!) of blood-derived 
fluid daily. Of this amount, less than 1% (1.5 L) typically leaves 
the body as urine; the rest returns to the circulation.
The JGC includes three populations of cells that help regulate 
the rate of filtrate formation and systemic blood pressure.
■ The macula densa (mak!u-lah den!sah; “dense spot”) is 
a group of tall, closely packed cells in the ascending limb 
of the nephron loop that lies adjacent to the granular cells 
(Figure 25.8). The macula densa cells are chemoreceptors 
that monitor the NaCl content of the filtrate entering the 
distal convoluted tubule.
■ Granular cells [also called juxtaglomerular (JG) cells] are in 
the arteriolar walls. They are enlarged smooth muscle cells 
with prominent secretory granules containing the enzyme 
renin (see p. 621). Granular cells act as mechanoreceptors 
that sense the blood pressure in the afferent arteriole.
■ Extraglomerular mesangial cells lie between the arteriole and 
tubule cells, and are interconnected by gap junctions. These 
cells may pass regulatory signals between macula densa and 
granular cells.
We discuss the physiological role of the JGC in the next section.
 Check Your Understanding
 4. Name the tubular components of a nephron in the order that 
filtrate passes through them.
 5. What are the structural differences between juxtamedullary 
and cortical nephrons?
 6. What type of capillaries are the glomerular capillaries? What 
is their function?
For answers, see Appendix H.
Kidney Physiology:  
Mechanisms of Urine Formation
If you had to design a system to chemically balance and cleanse 
the blood, how would you do it? Conceptually, it’s really very 
simple. The body solves this problem in the following way. First, 
it “dumps” cell- and protein-free blood into a separate “waste 
container.” From this container, it reclaims everything the body 
needs to keep (which is almost everything filtered). Finally, 
the kidney selectively adds specific things to the container, fine-
tuning the body’s chemical balance. Anything left in the con-
tainer becomes urine. This is basically how nephrons work.
Urine formation and the adjustment of blood composition 
involve three processes (Figure 25.9):
 Glomerular filtration. Glomerular filtration (“dumping into 
the waste container”) takes place in the renal corpuscle and 
produces a cell- and protein-free filtrate.
 Tubular reabsorption. Tubular reabsorption (“reclaiming 
what the body needs to keep”) is the process of selectively 
moving substances from the filtrate back into the blood. It 
takes place in the renal tubules and collecting ducts. Tu-
bular reabsorption reclaims almost everything filtered—all 
of the glucose and amino acids, and some 99% of the wa-
ter, salt, and other components. Anything that is not reab-
sorbed becomes urine.
Cortical
radiate
artery
Afferent arteriole
Glomerular
capillaries
Efferent arteriole
Glomerular capsule
Renal tubule and 
collecting duct
containing filtrate
Peritubular
capillary
To cortical radiate vein
1
2
3
Urine
Glomerular filtration
Tubular reabsorption
Tubular secretion
1
2
3
Three major
renal processes:
Figure 25.9 A schematic, uncoiled nephron showing the 
three major renal processes that adjust plasma composition. 
Each kidney actually has more than a million nephrons acting in 
parallel.
1
2
3
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Figure 1.1: Adjusted Prevalent Rates of ESRD and the Annual Percent Change. 
 
 
 
 
 
 
Note: The adjusted rate of prevalent cases of end-stage renal disease rose 2010 to 1,763 per million 
population, about 21 percent higher than that seen in 2000.  The symbols represent the percent changed 
from the previous year’s rate. 
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Figure 1.2: Stages of glomerular filtration rate (GFR) 
 
Note: units for GFR are expressed in ml/min/1.73 m2; adapted from United States Renal Data System 
2012 
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Figure 1.3: GFR categories in Chronic Kidney Disease 
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate. 
Note: Relative to young adult level.  In the absence of evidence of kidney damage, neither GFR category 
G1 nor G2 fulfill the criteria for CKD.  Adapted from KDOQI Guidelines, 2012: International Society of 
Nephrology 
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Figure 1.4: Causative factors and outcomes of kidney disease and co-morbidities. 
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CHAPTER 2: BACKGROUND AND RATIONALE OF THE STUDY 
Renal disease is associated with a range of complex alterations to metabolic functions, 
which has an effect on physiological attributes [16].  These issues (e.g. diabetes, infections, toxin 
buildup) had been previously shown to be pro-inflammatory [9]. It was later noted that 
inflammation negatively affected the body which lead to malnutrition and eventually PEW from 
the combination of malnutrition and increased energy expenditure [9]. 
Methods of intervention are aimed at reducing mortality and morbidity stemming from 
CVD in the ESRD population.  Previous research has established that causative factors subjected 
the body to inflammation and oxidative stress [9], [12].  Dietary intervention was thus aimed at 
combatting the complications that were attributed to inflammation and oxidative stress.  These 
interventions explored anti-inflammatories and antioxidants as possible forms of diet therapy.   
A study by Kaysen et al. [12] noted that chronic inflammation among ESRD population 
increases pro-inflammatory biomarkers (i.e. interleukins) that are known to induce anorexia 
(appetite loss) by suppression of nutrient intake.  Thus an ESRD patient with inadequate nutrient 
intake is not consuming foods that have a high content of anti-inflammatories or antioxidants.  
The low nutrient intake is not enough to offset the damage caused by ESRD complications. 
Both anti-inflammatories and antioxidants work by attenuating the buildup of markers 
responsible for oxidative stress and inflammation stemming from CVD and dialysis related 
factors.  Under a high prevalence of oxidative stress stemming from an imbalance of an oxidant-
to-antioxidant ratio, this increases the amount of oxidative damage [9]. Additionally, uremic 
conditions from toxin buildup in the blood also give rise to this imbalance [4]. Interestingly, 
serum albumin has anti-oxidant capabilities based on the fact that it is a free radical scavenger 
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and a toxic compound-binding agent, which are figures prominently in uremic environments 
[17].  This coincides with dialysis patients having a deficit in serum albumin [9].  In the presence 
of CVD, pro-inflammatory cytokines are secreted which are an indicatior of rising inflammation 
in ESRD patients [18] (responsible for decrease nutrient intake and the eventual PEW).  The 
anti-inflammatory would thus be aimed at lowering the increase in cytokines [9], [18].   
One possibility in the hemodialysis population involved administering Omega-3 
supplements (due to their cardio-protective properties) [19].  Dietary sources of omega-3 PUFAs 
are anti-inflammatory and also offer benefits for improving lipid profiles, decreasing oxidative 
stress, and blood pressure [20].  Thus a combination of protein and Omega-3 supplementation 
was evaluated (against a placebo) for its ability to improve inflammation and nutritional status 
(the omega-3 as the anti-inflammatory and the protein supplement to attenuate the loss of protein 
stores).    However, despite a marginal improvement in triglycerides, serum albumin levels were 
unaffected while no changes were observed in the normalized protein nitrogen appearance values 
and body mass index values [19].   
More research is needed to combat complications associated with ESRD including 
malnutrition and PEW since they lead to increased mortality risk. Omega 3 and protein 
supplementation has been examined, however, the results are not conclusive [19]. Vitamin E 
exists in two forms that differ from each other chemically and in terms of their biological activity 
[21].  The two forms tocopherols (TP) and tocotrienols (T3), vary according to the characteristics 
of the side chain [21].  Most documented studies on vitamin E refer to TP, which is commonly 
used in research and sold commercially as supplements [21]. Tocotrienols are more potent than 
TP in terms of biological activity: antioxidant capabilities are more potent than TP and their anti-
inflammatory effects were found to inhibit the secretion of biomarkers such as IL-6 [21], [22]. 
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Tocotrienols are part of the vitamin E family [23], [24].  As shown in figure 2.1, they are 
molecularly similar to TP and contain a chromanol ring, a hydroxyl group that has the ability to 
donate a hydrogen atom [25] and a farnesyl tail, which is hydrophobic.  The only difference 
between the two forms is the side chain on the T3 contains 3 double bonds at carbon number 
three, seven, and eleven, giving them a bent configuration [26].   T3 molecules have four 
isoforms: alpha, beta, gamma, and delta, which are determined by methyl group placement on 
the chromanol ring an vary in biological activity [23].  Tocotrienols circulate with the aid of a 
transfer protein [21], [27].  Though it has affinity for alpha-TP, they are still detected within 
plasma at very low concentrations [21], [27].  Postprandial studies of T3 reveal that in plasma 
delta-T3 peaked at approximately four hours and alpha/beta was at five hours after oral intake 
[28].  Size and mass of T3 are an average of 736.3 angstroms and 410.6 g/mol, considerably less 
than TP [25].  
 Tocotrienols are found in a vast array of foods, although the concentration is low 
compared to TP.  Currently, majority of supplements containing vitamin E are primarily TP [24].  
Tocotrienols are abundant in rice bran, wheat germ, oats, and palm fruit [24].  In fact, the oil 
extracted from palm oil has the highest concentration of T3 compared to other plant based 
sources [24].  Figure 2.2 summarizes the quantity of T3 listed from plant based sources [24].	  
Limited studies have discussed the benefits of T3 [29].  Although T3 may not be 
abundant based on low transfer protein affinity, the concentration is small enough for beneficial 
effects [26]. Beneficial effects of T3 spans across a multitude of attributes, however, anti-oxidant 
and anti-inflammatory properties are most notable.  The molecular structure of the T3, 
specifically the chromanol ring, contains a hydroxyl group that donates the hydrogen ion to 
scavenge reactive oxygen species and free radicals, a prominent effect of its anti-oxidant 
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capabilities [26].  T3 also induces other enzymes such as superoxide dismutase or glutathione 
peroxidase that takes up free radicals generated by environmental damage or oxidative stress 
[29].   
Benefits of T3 are still under investigation.  So far, T3 has been shown to be cardio-
protective and anti-cancer.  In some studies, T3 was detected among low density lipoproteins 
(LDL) while in transit and later found to prevent oxidation of those molecules [26].  Other 
cardio-protective attributes include T3’s ability to inhibit HMG-CoA reductase while 
suppressing inflammation [29] thereby reducing the patient’s LDL cholesterol.   With regards to 
cancer, a rat study showed that mammary carcinogenisis was prevented by way of blocking 
chemically induced tumorigenesis of the mammary glands [26].  It noted that T3 suppressed 
cells’ proliferation and perhaps induced apoptosis within the tumors [29]. 
The complications that stem from ESRD, dialytic factors, and co-morbidities subjects the 
body to inflammation, toxin buildup, and oxidative stress that ultimately leads to decreased 
nutrient intake, malnutrition and an eventual PEW [9].  It appears that T3 may be able to 
counteract the inflammation and oxidative stress based on its anti-inflammatory properties. An 
increase in pro-inflammatory cytokines may be inhibited, radicals produced during oxidative 
injury would be scavenged, and the oxidant-antioxidant ratio would improve to boost the overall 
antioxidant defense mechanisms.   Therefore, an ESRD patient on hemodialysis would lower 
their mortality risk based on the stabilization or inhibition of complications associated with the 
aforementioned factors. 
 
Figure 2.1: Molecule of Vitamin E 
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Adapted from: National Center for Biotechnology Information at the National Institutes of Health. 
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Figure 2.2: Quantity of tocotrienols listed from plant based sources. 
 
 
Adapted from www.tocotrienols.org 
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CHAPTER 3: OBJECTIVE 
 The primary objective of this study was to evaluate the nutritional status of the 
hemodialysis patients and to see if intervention with T3 supplements had any effect on their 
status.  This was viewed based on probable change to the patients’ anthropometric measurements 
and biochemical profiles.  Complications of nutritional status such as PEW, the depletion of 
body mass, can be accounted for in BMI since that is a measure of lean body mass [9].  It had 
been established that reduced kidney function, dialytic factors, and co-morbidities raise 
inflammation which increases energy expenditure while depleting the body stores due to 
inadequate nutrient intake [9]. The effects of inflammation cause a decrease in appetite, thereby a 
decrease in nutrient intake resulting in a protein catabolic state of PEW since there was nothing 
to attenuate an increase in energy expenditure [9], [11]. 
 The nutritional status of the patients on hemodialysis required a diet assessment so that 
the recall tracked the nutrient intake.  Another value to the diet recall allowed the detection of T3 
intake from foods consumed based on previous research.  The supplementation of T3 was also 
taken into account so that the total intake was determined.  Another aspect the research was 
analyzing the biochemical profile of serum albumin.  Albumin’s role is used to assess protein 
status, also known as visceral protein concentration [9].  Other biochemical profiles required to 
assess inflammatory status relies on the cytokine or interleukin concentrations [9].    
There have been a limited number of studies that evaluate the effects of dietary 
intervention as seen in the Kuhlmann et al. that discussed anti-inflammatory 
diet/supplementation and reducing CVD risk.  With respect to hemodialysis studies, we know 
that mortality risk is reflected in the presence of vascular disease [30] and an increase in PEW 
due to malnutrition and inflammation [10], ultimately encompassing CVD [9].    
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A connection had been established which states that PEW and mortality is reflected in 
serum albumin concentrations, as discussed by Jadeja et al.  Diagnosis is often reflected in a 
comparison between nutritional requirements in CKD such as total caloric and protein 
requirement in accordance with the National Kidney Foundation’s Kidney Dialysis Outcome 
Quality Initiative (KDOQI) guidelines (between 0.6-1.2 grams of protein/kg body weight 
depending on CKD stage and 30-35 kcal/kg body wt).  There are no official recommendations on 
supplementation because the studies recommend the importance of protein and energy 
consumption while putting some emphasis on consumption of micronutrients such as 
antioxidants, vitamins, and certain minerals.  The object is to attenuate the loss in protein stores 
due to renal disease and complications associated with dialytic factors co-morbidities. 
 Under the main outcome measures, the use of clinical profiles was required.  This 
entailed a recording of nutrient data so that nutrient consumption was determined, in addition to 
tocotrienol consumption via food intake.  Nutritional focused physical findings were also 
required such as anthropometric measurements of BMI and body weight that provided a visible 
outcome to nutritional problems.  Finally, biochemical profiles were analyzed from blood 
samples which allowed the researchers to determine serum albumin to asses visceral protein 
concentrations (must be around 4 g/dL according to KDOQI guidelines) [9] which is a good 
predictor for mortality [3].  These are non-traditional factors whereas traditional risk factors for 
mortality tend to be opposite in ESRD patients (low serum cholesterol as a high risk factor for 
mortality) [9] and modifiable factors may not be applicable to the ESRD population compared to 
the normal population [9]. 
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CHAPTER 4: MATERIALS AND METHODS 
 
 This project involved a collaborative effort of both Wayne State University Nutrition and 
Food Science and the Great Lakes Dialysis Center in Detroit, Michigan.  The study’s patients 
received routine hemodialysis treatment 4 days a week from the Great Lakes Dialysis Center.   
 The study conducted was parallel designed, randomized, and placebo controlled.  The 
parallel design consisted of two groups within this dialysis participant study that were randomly 
given two different types of treatment.  This clinical trial approach allowed the researchers to 
analyze and evaluate the outcomes of both types of treatment. 
 Under this study design, nutritional intervention of the groups were given either placebo 
or supplement capsules that were administered to the patients for dialysis and non-dialysis days.  
The key objective for the dialysis days was that it allowed the researchers to have a direct 
observation of treatment, making it easier to monitor the patients’ compliance when taking the 
capsules.  On the non-dialysis days, the patients were provided capsule organizers where each 
container had a compartment for each day of the week.  These patients were grouped according 
to dialysis treatment: Sunday, Tuesday, Thursday, and Saturday; and Monday, Wednesday, 
Friday, and Sunday. 
The supplements (Carotino, Johor Darul Takzim, Malaysia) were provided to both groups 
within the study population consisted of a placebo capsule and the tocotrienol rich fraction (TRF) 
capsule.  The two groups were designated Placebo and TRF based on the supplements that were 
administered.  The placebo capsule contents consisted of wheat germ oil that is 0.24 miligrams 
of tocotrienols and 0.44 milligrams of tocopherols.  The TRF capsule contents consisted of Palm 
fruit oil that contained 90 milligrams of tocotrienols and 20 milligrams of tocopherols, for a total 
of 110 milligrams of vitamin E.  To ensure compliance, the patients under directly observed 
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treatment were provided with two capsules during dialysis days three times a week.  A weekly 
organizer was provided with capsules to be taken on non-dialysis days during the two main 
meals.  The containers were returned each week and then refilled. 
 Another aspect of the study design was the 24-hour dietary recall performed by the 
registered dietitian.  Each patient gave a recall at both baseline and then at week 16.  The 
Nutritionist Pro software (First Databank, Chicago, IL) was used at the Wayne State University 
labs to complete the analysis after manually transcribing the hand-written recalls into the 
program.  Estimations of portion size and quantity were recorded at the dialysis center and later 
transcribed by the Wayne State lab graduate research students.  This kept track of the nutrient 
(macro and micro) and energy intake for all the participants.  The total calories consumed during 
both time points, especially at week sixteen, gave an indication of whether or not the patients 
were consuming enough energy based on the recommended values. The macronutrients (i.e. fats, 
carbohydrates, protein) and the micronutrients (i.e. vitamins, minerals) were provided so that 
percentages of the diets were calculated in terms of composition.  The data was then analyzed 
further utilizing statistical analysis software SPSS.  It manipulated the data in order to determine 
food intake behavior based on group mean differences that used independent t-tests, chi-square 
tests for categorical data, and Pearson’s correlation coefficients for correlation tests between two 
variables while significant P-values are <.05. 
 The 24-hour diet recall contained a very important aspect of the study since it was 
necessary that some foods consumed by the patients had naturally occurring tocotrienols.  
Previous research conducted by various institutions had determined the content of tocotrienols 
contained in processed foods.  The tocotrienols are naturally found in oils, grains, and some 
animal products like eggs.  The Wayne State nutrition labs pooled the data from the various 
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resources and created a database to determine the tocotrienol content of the foods [38-43].  Data 
was provided in milligrams of tocotrienols per kilogram (or 100 grams) of the food item.  This 
was calculated according to the actual weight of the patients’ food that determined the 
approximate amount of tocotrienols consumed.   
 Laboratory analysis of blood samples was performed for the patients at baseline and 
week 16 which obtained the biochemical profiles of both serum albumin and IL-6.  Serum 
albumin was analyzed at an external laboratory via standard automated laboratory techniques 
(Bromocresol Green assay, Satellite Laboratory Services, Redwood City, CA). IL-6 was 
measured via the ELISA method per manufacturer protocol (Thermo Scientific, Cat No. 
EH2IL6).  In addition to blood sample collection, medical professionals at the dialysis center 
recorded anthropometric measurements such as weight and BMI at the dialysis clinic.    
 In summary, the methods involved with the study for laboratory analysis at week zero 
and week sixteen were as follows: blood collection for serum albumin and IL-6 content that was 
analyzed for protein content and inflammatory markers; clinical profiles (i.e. body weight, BMI) 
that allowed the researchers to determine any fluctuations that may have indicated a decline 
(stemming from protein energy wasting); dietary analysis based on 24-hour diet recall was 
manually input into the Nutritionist Pro software and tocotrienols were calculated using external 
databases to analyze the nutrient intake (both macro and micro nutrients).  Information on total 
calories, protein, and tocotrienols provided some insight into the possibility of malnutrition. 
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CHAPTER 5: RESULTS 
 Tables 5.1 through 5.10 depict the patients’ clinical characteristics and nutrient intake 
data for baseline and week 16.  The baseline values were recorded at the beginning of the study.  
At the end of the study, a comparison of the data between the two time points was made. The 
goal of the TRF supplements administered in comparison to a placebo was to observe a possible 
difference in the nutrient, clinical, and biochemical profiles of the patients’ data. 
 Table 5.2 depicts the clinical characteristics of the study population.  The BMI intervals, 
in accordance with the Center for Disease Control (CDC), are expressed in terms of kg body 
wt/m2.  The intervals are as follows: underweight (<18.9), normal (19-24.9), overweight (25-
29.9), obese (30-34.9), very obese (35-39.9), and morbidly obese (40<).  The average BMI for 
the study population was approximately 29.5 ± 8.1, which is overweight under CDC guidelines 
and an average of the placebo and TRF groups (28.7 ± 8.2 and 30.2 ± 8.1, respectively).  
Between the two groups, there was no difference throughout the range.  In terms of distribution, 
majority of the patients were in the 19 to 29.9 BMI level. This distribution did not change at the 
end of the study, as the values were the same; majority of patients fell into the 19-24.9 and 25-
29.9 ranges.  Furthermore, there was no significance at either time point. 
The next two measurements in table 5.2 were the biochemical profiles of serum albumin 
and IL-6.  Serum albumin levels read at an overall average of 3.9 ± 0.3 g/dL.  There was no 
difference between the placebo and TRF groups at both times. Moreover, nothing was significant 
after the t-tests were ran.  The three distribution levels were determined by the SPSS software 
based on frequencies of levels for the patients.  The KDOQI guidelines state that an approximate 
value of 4.0 g/dL represents a normal value for the dialysis population, and a significant drop 
indicates a decline in protein status further adding to the risk of mortality.  It may appear that the 
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distribution started off with the majority of patients at 3.8 or less at week zero, but week 16 had 
most of them in the 3.9-4.1 range.  The placebo group in week 16 had only three people move up 
into the 3.9-4.1 and 4.2 groups, however, no change in distribution.  The remaining patients were 
removed from the study since denoted by the reduction in population from 40 to 36.  Since the t-
test proved no significance, again, these values did not change.   
Biomarkers of inflammatory status, such as IL-6, can be viewed in table 5.2.  At the 
beginning of the study, the average for the patients was at 6.9 ± 6.7 pg/mL.  This translated into 
around 7.9 ± 7.9 pg/mL for the placebo and 5.8 ± 5.1 pg/mL for the TRF groups.  There was no 
variation at baseline between the groups considering their averages were about 2 pg/mL apart 
and that there was no significant difference determined by the t-tests. At the end of the study, 
these values did not change and still had no significant difference between the groups.   
The remaining tables, 5.3-5.10, provide information on nutrient intake and possible 
relationships among individual macro and micronutrients in addition to the biochemical and 
anthropometric profiles.  In table 5.3, the average energy and macronutrient intake was provided 
for baseline and week 16 time points based on mean comparisons.  As expected, baseline values 
should have no significant difference since nutrient data was acquired from the patients before 
the supplementation was administered. The average for all patients measured at 2013 ± 727 kcals 
per day.  This accounts for 2097 ± 848 for the placebo and 1932 ± 585 for the TRF groups.  
However, there was no significant difference.  This translates into a low kcal/kg body weight 
measurement at 25 ± 12 kcal/kg body wt for the average.  Again, the two groups had no 
significant difference following the t-test even though the placebo group consumed 
approximately 27 ±14 kcal/kg body wt and the TRF consumed 23 ± 9. In addition, these 
averages are below the KDOQI recommendation of 35 kcal/kg body weight except for the 
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patients.  Over all, these averages that fall below the recommendations suggest there is presence 
of under-nutrition in terms of total calories. At week 16, the average intake was approximately 
1807 ± 481 kcal/day.  However between the groups, there was no significant difference and 
overall no change in comparison to the baseline values.  
In table 5.3, protein consumption was tracked but the values did not come up significant.  
Even though the baseline average of 94 ± 52 g which is 96 ± 68 g for the placebo and 91 ± 31 g 
for the TRF groups.  With a p-value of 0.074, it had a tendency to be significant based on the p 
value that is greater than .05 but less than .1.  Per the KDOQI guidelines (1.2 g/kg body wt), only 
the placebo group managed to reach that value at about 1.24 ± 0.77 g/kg body wt.  This makes 
the overall consumption falls below to the amount of 1.16 ±.62 g/kg body wt when TRF is 
factored in as it only had 1.08 ± .42 g/kg body wt.  A relatively large standard deviation like this 
may explain why the range of protein consumption per bodyweight varies so much.  This pattern 
remained the same at week 16, no change in numbers and there was no significant difference 
between the groups.  Overall consumption was 90 ± 51 g, which is 83 ± 33 g for placebo and 95 
± 62 g for TRF. 
The next macronutrient on table 5.3, carbohydrates, had no significant difference between 
the two groups at both time points.  Carbohydrate intake for all groups was evaluated at roughly 
219 g ± 104 g (220 ± 103 g for placebo and 218 ± 107 g for TRF) at baseline and 202 ± 75 g 
(198 ± 65 g for placebo and 206 ± 83 g for TRF) at week 16.  
Cholesterol intake, on table 5.3, was valued at an average of 431 ± 335 mg, placebo (448 
± 274 mg) and TRF (415 ± 388 mg) groups did not differ because there was no significant 
difference.  There were unchanged values at week 16 indicated by an average of 397 ± 436 mg 
(353 ± 247 mg for placebo and 433 ± 544 mg for TRF) with no significance based on the t-tests.  
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Among the remaining lipids, total fat intake for the patients was 89 ± 48 g, which 
comprises of 99 ± 57 g for the placebo and 80 ± 36 g for the TRF groups, with a p value of 
0.084.   The difference between the groups had a tendency to be significant since the p-value is 
between .05 and .1.  At week 16, total fat intake was at an average of 75 ± 30 g, &1 ± 24 g for 
the placebo and 79 ± 34 g for the TRF group, but no significant difference.  Saturated fat intake 
fluctuated around 31 ± 26 g at baseline (36 ± 18 g for placebo and 29 ± 31 g for TRF), but was 
not significant.  At week 16, there was no change since the average was 26 ± 23 g (21± 8 for 
placebo and 30 ± 30 g for TRF), but they had a tendency to be significant since the t-test’s p 
value was 0.076. MUFAs, with a significance of .05, was detected at an intake of 31 g ± 20 
overall, which is roughly 36 g  ± 24 for the placebo and a lower intake of 27 g ±15 for the TRF 
group.  Week 16 intake had an average of 24 ± 13 g overall, 23 ± 10 g for placebo, and 25 ± 15 g 
for TRF, which had a tendency to be significant (p-value = .067) but again no change.  PUFA 
intake was the lowest intake for both groups with 18 ± 13 g overall, 19 ± 15 g for the placebo 
group, and 17 ± 11 for the TRF group, all with no significant difference.  The week 16 values 
were at an average of 15 ± 12 g (15 ± 11 g for placebo and 16 ± 13 g for TRF) with no 
significant difference.  
The next table, 5.4, presents the average intake for the remaining nutrients evaluated for 
the study population. Sodium intake at baseline was at an average of 3019 ± 1845 mg for all, 
which is 2961 ± 2000 mg for placebo and 2074 ± 1705 mg for TRF, but no significant 
difference.  Week 16 sodium intake values does not show a change based on the average of 3352 
± 1628 mg for all, 3256 ± 1531 mg for placebo, and 3429 ± 1720 mg for TRF, with no 
significant difference.  These values are above the recommended intake of 2 g per day [31].  
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The intake for potassium (see table 5.4) was also not significant.  The baseline values are 
at an average of 2371 ± 2334 mg, 2295 ± 1115 mg for placebo, and 2371 ± 2333 mg for TRF, 
but no significant difference.  For week 16, intake was at an average of 2015 ± 919 mg, 1962 ± 
961 mg for placebo, and 2058 ± 894 mg for TRF, with no significant difference.  Moreover, 
potassium intake was well within the recommended intake of 2-3 g/day [31].   
Vitamin A intake, well above recommendations [31], was determined at in average intake 
of 7371 ± 19372 mg, which is 5524 ± 7415 mg for placebo and 9172 ± 26273 mg for TRF at 
baseline.  The reason for high standard deviation is that one of the patients consumed a high 
amount of vitamin A by eating 16 ounces of liver in one day after reviewing their diet recall.  
Moreover, these differences were not significant.  At week 16, average intake was 6015 ± 9645 
mg, 6377 ± 12115 mg for placebo, and 5718 ± 7193 mg for TRF.  Again, there was no 
significant difference.   
Vitamin C intake (See Table 5.4), a water-soluble vitamin, is at risk for severe depletion 
during the dialysis process.  It is recommended that there should be an intake 60-100 mg/day to 
attenuate this loss [31].  At baseline, the average intake was 99 ± 84 mg, which was about 90 ± 
81 mg for placebo and 108 ± 86 mg for TRF.  This had a tendency to be significant based on the 
fact that the p value (0.064) is between .05 and .1.  At week 16, average intake was 90 ± 105 mg, 
102 ± 112 mg for placebo, and 80 ± 98 mg for TRF with no significant difference.   
Vitamin E-TP (see table 5.4) (tocopherol) intake had no significant difference at baseline 
or week 16.  The average baseline intake was recorded at approximately 10 ± 10 mg, 9 ± 9 mg 
for placebo, and 10 ± 10 mg for TRF.  At week 16, average intake was 6 ± 4 mg, 5 ± 3 mg for 
placebo, and 6 ± 5 mg for TRF.   
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The intake of Total T3s (table 5.4) at baseline was taken before the study began and was 
detected at an average of 2 ± 4 mg, 2 ± 4 mg for placebo, and 3 ± 4 mg for TRF with no 
significant difference.  In week 16, interestingly, the values included supplement intake and were 
significant with a p-Value of <.0001.  The average intake was 92  ± 91 mg, 2 ± 1 mg for placebo, 
182 ± 3 mg for TRF.  Dietary T3 intake at week 16 was at an average of 2 ± 2 mg, 2 ± 1 mg for 
placebo, and 2 ± 3 mg for TRF.   
Another nutrient evaluated in the diet recalls was phosphorous (see table 5.4).  Average 
baseline intake was 1173 ± 589 mg, 1159 ± 601 mg for placebo, and 1186 ± 585 mg for TRF, 
with no significant difference.  At week 16, average intake was 996 ± 469 mg, 953 ± 431 mg for 
placebo, and 1031 ± 500 mg for TRF.  These values appear to be at the recommended level [31].   
The remaining nutrient intake, calcium, iron, and dietary fiber, are displayed on table 5.4 
and neither one of them had any significant differences at baseline or week 16.  Their 
relationships can also be viewed on tables 5.6-5.10 for any (significant) correlations.  After 
analyzing both the mean values of the nutritional intakes for both time points, there appears to be 
little or no difference at all.  This applies to the overall values as well as for the placebo and T3 
groups.  
Table 5.5 depicts the baseline and week 16 macronutrient correlation coefficients.  This 
data would hold the behavior of certain macronutrient intake patterns in comparison with other 
macronutrients.  The correlation coefficients that are displayed indicate that the relationship 
between the two nutrients is significant.   
Total calories have positively correlated with all the macronutrients at baseline and 
continued their relationship with all except Saturated Fat and PUFA.  Saturated Fat and PUFA 
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intake did not have any correlation with Total Calories because the relationship was not 
significant.  Further examination of protein intake did show a (positive) correlation with all 
nutrients except saturated fat and PUFA (at week 16 only) because they were not significant.   
Carbohydrates only had positive correlation with total calories and protein at both baseline and 
week 16.  Total fat intake positively correlated with all the nutrients displayed in table 5.5 except 
carbohydrates at baseline and week 16.  Cholesterol also positively correlated at baseline and 
week 16 with all nutrients except carbohydrates and saturated fat, but only at baseline with 
PUFA.  Saturated fat only positively correlated with Total Calories at baseline only, with Fat at 
baseline and week 16, but only with MUFA and PUFA at baseline.  MUFA had positive 
correlation Total Calories, Protein, Fat, Cholesterol, and PUFA at baseline and week 16.  MUFA 
did correlate with Saturated Fat only at baseline.  PUFA correlated with Total calories, protein, 
Cholesterol, and Saturated Fat at baseline only, and with Fat and MUFA at both baseline and 
week 16. 
Table 5.6 displays the baseline and week 16 micronutrient correlation coefficients 
between Total Calories, Sodium, Potassium, Vitamin A, Vitamin C, Calcium, Iron, Vitamin E 
(tocopherols), Phosphorous, Dietary fiber, dietary Vitamin E-T3, and Total T3 (dietary + 
supplement).  Total T3 at baseline only consists of dietary sources of T3 because supplements 
were not administered when the first diet recall was recorded.  According to this data, Total 
Calories positively correlated with Sodium, Potassium, Calcium, Iron, Vitamin E-TP, 
Phosphorous, and Dietary Fiber at baseline and week 16.  Total calories also correlated with 
Vitamin C only at week 16.  The remaining nutrients had no correlation with Total Calories since 
they were not significant.  Sodium and Phosphorous had a positive correlation at baseline and 
week 16, but with Potassium, Calcium, Iron, and Dietary Fiber at week 16 only.  Potassium 
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positively correlated with Vitamin C, Calcium, Iron, Phosphorous, and Dietary Fiber at baseline 
and week 16.  Vitamin A positively correlated with Iron and Phosphorous at baseline and with 
Dietary Fiber at week 16.  Vitamin C also had positive correlation Iron, Vitamin E-TP, 
Phosphorous, and Dietary Fiber at baseline only.  Calcium had additional positive correlation 
with Iron, Phosphorous, and Dietary Fiber at both baseline and week 16.  Iron positively 
correlated with Phosphorous and Dietary fiber at baseline and week 16, but only with Vitamin E-
TP at baseline, in addition to the other relationships previously discussed.  Vitamin E-TP also 
had positive correlation with Phosphorous at baseline and with Dietary Fiber at week 16.  
Phosphorous additionally had positive correlation with Dietary Fiber at baseline and week 16 
and with Vitamin E-T3 at baseline only.  Dietary Fiber, in addition to other nutrients, positively 
correlated with Vitamin E-T3 at baseline and week 16.  Vitamin E-T3 did not have any further 
relationships with nutrients other than what had been mentioned previously because there was no 
significance.  This applies to all the nutrients within Table 5.6, no presence of a correlation 
coefficient means that there was no significance between the two nutrient comparisons. 
Table 5.7 contains the baseline and week 16 correlation coefficients between Total 
Calories and Protein with anthropometric and biochemical profiles.  Based on the data provided 
on the nutrient intakes, anthropometric, and biochemical profiles, serum albumin did not have 
any interaction with any nutrient intake or biomarker.  While further examining relationships IL-
6 had with nutrients and biomarkers, there was a positive correlation only with dietary T3 which 
suggests IL-6 occurrence is higher with an increased intake of dietary T3.  At the end of the 
study, IL-6 had no correlation with any nutrient or biomarker because they were not significant.   
BMI had a positive relationship with protein intake, Triglyceride levels, and a negative 
relationship with HDL cholesterol.  The latter two are in conjunction with previous literature on 
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the kidney disease population stating that high BMI is associated with higher triglycerides or 
lower HDL cholesterol [32].  At week 16, BMI continued to have a negative correlation with 
HDL cholesterol, agreeing with BMI-HDL relationship in previously established literature.   
The following biomarkers were analyzed based on informational purposes to see if there 
is any conjunction with lipid profile data.  Total Cholesterol (serum) only had positive 
correlation with Triglycerides at week 16, and LDL Cholesterol at both baseline and week 16.  
This claim is agreeable with previous literature [32].  Triglycerides negatively correlated with 
HDL cholesterol at baseline and week 16, in addition to, LDL cholesterol at week 16 only.  HDL 
cholesterol also had a negative correlation with LDL cholesterol at week 16, which is already 
established in prior literature [32]. 
Table 5.8 depicts the interaction between macronutrients and biochemical profiles at 
baseline and week 16.  Based on the data provided, there was no correlation between the 
nutrients and the biochemical profiles.  However, there is an additional correlation test 
comparing Dietary Fiber with the other nutrient intakes and it was shown that it had positively 
correlated with Total Calories and Carbohydrates at baseline and week 16, but negatively 
correlated with (dietary) Cholesterol.  The latter may suggest that those consuming fiber rich 
foods may consume less dietary cholesterol, or vice-versa. 
Table 5.9 contains data on the baseline and week 16 interactions between Vitamin E, 
biochemical, and anthropometric correlations.  The relationship between the biochemical and 
anthropometric profiles had already been discussed in table 5.7. Vitamin E-T3 and Total-T3 both 
had positive correlation with IL-6 at baseline.   
	  	  
33	  
The final table, 5.10, contained data that depicts the baseline and week 16 correlation 
between T3 and macronutrients.  Correlation among the macronutrients had already been 
discussed in table 5.5.  Between Vitamin E-T3 and the macronutrients, there was negative 
correlation with Cholesterol intake at baseline and positive correlation with Saturated Fat at 
week 16.   
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Table 5.1: Demographics and clinical characteristics of the study population. 
 
Note: All values are presented as mean ± Standard Deviation except for gender and ethnicity.   
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Table 5.2: Baseline and week 16 anthropometric and biochemical profile data. 
 
 
1. Values in accordance with the Center or Disease Control, kg body weight/(height in meters)2  
2. KDOQI guidelines state that serum albumin equal to or greater than the lower limit of normal range (approx. 
4.0 g/dL for the Bromcresol Green Method) is the outcome goal 
Note: all values are presented as mean ± standard deviation.  P values derived using independent t-test for IL-6; BMI 
and serum albumin using χ²  for categorical variables for each time point.  *All non-significant unless denoted by a 
p-value otherwise.  Overall there was no change in values from baseline to week 16.  The distributions of BMI and 
Serum Albumin also remained the same due.  It is suggested that caloric intake is the main cause do to the 
unlikelihood of increased physical activity.  Additionally, there could be limitations to the study based on the fact 
that the 24-hour diet recalls were collected and evaluated at 2 time points and therefore unable to assess dietary 
activity between the 16 weeks.  E.g.: the decline of 3 participants in 16 weeks from the 19-24.9 range could be 
attributed to patient disqualification since one is not accounted for if 2 patients experienced an increase in BMI. 
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Table 5.3: Baseline and week 16 macronutrient data.  
 
Note: All values are presented as mean ± standard deviation.  P-values derived using independent t-tests for each 
time point.  Protein intake at baseline along with saturated fat and MUFA at week 16, have a tendency to be 
significant.  Normally this suggests that the p-Value is greater than 0.05 or less than 0.1. 
* All non-significant unless denoted by a p-value otherwise. 
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Table 5.4: Baseline and week 16 micronutrient data.  
 
1. alpha-tocopherol 
2. Combined tocotrienols from food + supplements for week 16 only. 
Note:  all values are presented as mean ± standard deviation.  P-values derived using independent t-test between the 
two groups for each time point. 
Vitamin C intake at baseline has a tendency to be significant. 
* All non-significant unless denoted by a p-value 
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Table 5.5: Baseline and week 16 macronutrient correlation coefficients. 
 
Note: Week 16 values are bold face and italicized.  E.g., total calories and protein is significant with a 
correlation coefficient value of 0.671.  Only those with correlation values between the two variables are 
displayed.  Those with blank fields are not significant and therefore have no correlative relationship. 
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Table 5.6: Baseline and week 16 micronutrient correlation coefficients. 
 
1. Vitamin E-T3 is dietary sourced T3 
2. Total T3 is a combination of dietary sourced T3 and supplements. 
Note: Week 16 are in bold face point and italicized.  E.g., total calories and sodium is significant with a correlation 
coefficient value of 0.567.  Only those with correlation values between the two variables are displayed.  Those with 
blank fields are not significant and therefore have no correlative relationship. 
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Table 5.7: Baseline and week 16 anthropometric and biochemical profile correlation coefficients. 
 
Note: Week 16 values are in bold face point and italicized.  E.g., total calories and protein is significant with a 
correlation coefficient value of 0.671.  Only those with correlation values between the two variables are displayed.  
Those with blank fields are not significant and therefore have no correlative relationship.   Other notable attributes: 
this suggests that BMI increases when triglycerides increase and decreases with HDL cholesterol increases.  
Triglycerides decrease with HDL cholesterol increase and HDL cholesterol increase entails an LDL cholesterol 
decrease due to cholesteryl ester transfer protein (CETP) activity.  These statements are all in accordance that were 
established in previous findings.  
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Table 5.8: Baseline and week 16 macronutrient and biochemical profile correlation coefficients. 
 
Note: Week 16 values are in bold face point and italicized.  E.g., total calories and protein is significant with a 
correlation coefficient value of 0.671.  Only those with correlation values between the two variables are displayed.  
Those with blank fields are not significant and therefore have no correlative relationship. 
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Table 5.9: Baseline and week 16 Vitamin E, biochemical, and anthropometric correlation coefficients. 
 
1. Vitamin E-T3 is dietary sourced T3. 
2. Total T3 is a combination of dietary sourced T3 and supplements. 
Note: Week 16 values are in bold face point and italicized.  E.g., total T3 and Vitamin E-T3 is significant with a 
correlation coefficient value of 1.000.  Only those with correlation values between the two variables are displayed.  
Those with blank fields are not significant and therefore have no correlative relationship. 
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Table 5.10: Baseline and week 16 Vitamin E and macronutrient correlation coefficients. 
 
1. Vitamin E-T3 is dietary sourced T3. 
2. Total T3 is a combination of dietary sourced T3 and supplements. 
Note: Week 16 values are in bold face point and italicized.  Only those with correlation values between the two 
variables are displayed.  Those with blank fields are not significant and therefore have no correlative relationship. 
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CHAPTER 6: DISCUSSION 
 The focus of this study is to analyze the nutritional status of patients with ESRD 
undergoing hemodialysis.  Specifically, to study the effect of a prescribed vitamin E supplement 
on complications of ESRD of these patients. ESRD is the result of CKD after a gradual loss in 
kidney function as the rate at which blood flows through the glomeruli to filter out byproducts, 
falls to less than 15 mL/min/1.73m2[1].  A buildup of waste products in the blood damages the 
blood vessels (also known as nephropathy).  This causes the kidneys to fail, which makes 
hemodialysis as a form of renal replacement therapy necessary.  Prevalence of ESRD has been 
on the rise since the 1980s according to the USRDS.  ESRD afflicts a certain number of 
Americans, especially African Americans who constitute 33% of the 400,000 patients seeking 
dialysis treatment. ESRD continues to be the highest for African Americans compared to other 
ethnicities [2], [3].  However, between mortality and survivability, certain factors show the 
African American dialysis patients have a greater survival rate than Caucasian patients [1](e.g. 
body mass, lipid profiles) [2].   
 Based on current research, causes of CKD and ESRD stem from multiple factors.  Drug 
use can affect intra-glomerular blood flow, lead to cell injury via cytotoxicity, and cause crystal 
induced obstruction of the vessels [7].  During hypertension, high blood pressure forces the heart 
to work harder over time, thereby damaging blood vessels throughout the body, including blood 
vessels within the kidneys [8].  Those inflicted with diabetes have higher levels of blood sugar 
that causes the kidney filters to become overloaded due to the extra work, eventually failing [8].  
Early signs of diabetes induced kidney failure is detected by protein found in urine [8].  As a 
result, ESRD has an impact on morbidity and mortality of the patients as evidenced by increasing 
risk of hospitalizations and long term complications, including cardiovascular disease, 
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malnutrition, and chronic inflammation [9].  The risk for cardiac events is higher in this 
population, thereby contributing to their risk of mortality [9]. 
 Researchers have been forced to explore nontraditional risk factors contributing to 
morbidity within the ESRD population.  Ikizler et al. noted that traditional risk factors towards 
mortality in the ESRD population appear to be contrary to effects in the normal, healthy 
population. For example, low serum cholesterol is protective in the general population but 
opposite in the ESRD population, and high body mass which is normally a risk factor in the 
general population is protective for those with ESRD [9].  Other risk factors contributing to 
morbidity in ESRD patients include anemia, disturbance in mineral metabolism, oxidative stress, 
chronic inflammation, and uremic malnutrition [9].  Chronic inflammation, oxidative stress, and 
malnutrition are especially important in the clinical outcomes of the ESRD population [9] since 
they can affect body composition. 
 One of the major issues that is associated with dialytic and ESRD related conditions, is 
the amount of inflammation the body endures.  Inflammation can stem from multiple origins, 
including vascular disease [12], [13], dialytic factors (e.g. incompatible dialyzer membranes, 
reduced kidney function), and co-morbidities (e.g. infections) [9].  Other sources of 
inflammation can result from uremic toxin buildup [4].  Interestingly, oxidative stress too can 
increase inflammation within the body, which is caused by a buildup of toxins and decreased 
antioxidant intake stemming from malnutrition [9].  It has been found that specific cytokines 
such as interleukins (IL-6) were found to be present during inflammation in addition to the 
accumulation of AGE products [9], [12].  This eventually lowers antioxidant defenses (e.g. 
serum albumin [9], [17]) against oxidative injury in addition to the suppression of appetite 
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(anorexia), which causes a decrease in nutrient intake (malnutrition), especially antioxidant 
intake [9], [13].  Additionally, inflammation has also has been found to increase REE [9].   
 Malnutrition and chronic inflammation have been found to be direct results of 
multifaceted effects of dialytic and co-morbid conditions.  This ultimately leads to strong clinical 
outcomes and increased mortality risk [11], [12]. Ikizler et al. provided a systemic approach to 
the effects and root causes surrounding malnutrition and inflammation discussed in figure 1.4. 
These inflammatory responses to ESRD complications were found to have caused a reduction in 
appetite and further increased energy expenditure denoted by an increase in REE [9].  This 
becomes a net catabolic protein state in which the body is forced to rely on its own protein stores 
for energy, resulting in a loss of body mass, also known as PEW [11], [10].   
 CVD is a common clinical outcome in ESRD patients due to the increase in mortality risk 
[15].  The ESRD patients are also at risk for hospitalization due to poor nutritional status and 
inflammation stemming from dialysis and co-morbid related issues [15].  Malnutrition and 
inflammation play a role in mortality since they impact nutritional and inflammatory markers 
that link CVD with ESRD.  This may suggest that ESRD patients should be encouraged to 
control aforementioned health complications in order to sustain health maintenance. 
 The objective of this project was to evaluate nutritional status of hemodialysis patients 
while undergoing an intervention of T3 supplements.  The effects can be viewed through 
probable changes to the patient’s anthropometric (BMI) and biochemical profiles (serum 
albumin, IL-6).  The anti-inflammatory characteristic of T3 is a key component by way of 
attenuating the effects of damage brought forth by inflammation where it may combat the rise in 
inflammatory markers.  Additionally, many improvements have been made on the oxidant-
antioxidant ratio, attenuation to the loss of serum albumin, as well as the possible defense 
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towards prevention of inflammation.  Many components of inflammation stem from decreased 
renal function, dialytic factors, and co-morbidities (i.e. diabetes, CVD, infections) [13], [12], [9].  
Moreover, the properties of T3 could potentially attenuate the loss of albumin as an antioxidant 
defense mechanism, thereby restoring the oxidant-to-antioxidant ratio to a normal level.  
Additionally, the immune response is a form of an acute phase response that triggers the 
stimulation of cytokines and interleukins, which can reduce antioxidant levels [12], thereby 
inducing oxidative damage.  Tocotrienols allow the hydroxyl group that donates a hydrogen ion 
to later scavenge reactive oxygen species and free radicals, which is one of its prominent  anti-
oxidant capabilities [26].  Another antioxidant property of T3  is the  induction of other enzymes, 
such as superoxide dismutase or glutathione peroxidase, that take up free radicals generated by 
environmental damage or oxidative stress [29].  
 Records of dietary intake and blood samples were taken and evaluated at two time points: 
baseline (Week 0) and Week 16.  Changes in biomarkers and nutritional status were observed.  
Nutritional status is based on both macro and micro nutrient intake and compared to the NKF’s 
KDOQI guidelines.   
 As mentioned before, anthropometric measures were observed at the beginning and the 
end of the study.  This allowed the researchers to see whether nutritional status had any impact 
on the measurements while T3 supplements were prescribed.  It appears that no change was 
detected in the patients’ BMI.  There was no change in the average BMI values of both study 
groups (roughly 30 kg/m2, 29 kg/m2 for placebo, and 30 kg/m2 for TRF), as well as in the 
distribution (the majority of patients were in the 19-24.9 and 25-29.9 ranges) at both time points. 
Moreover, it appears that the decrease in patients from the second interval may be partly due to 
the reduction in patients from the study.  One will also notice that the number of participants is 
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lower in week 16 compared to baseline.  BMI did have a positive correlation with protein intake 
at week zero, considering the relationship between protein and body mass and how the body 
requires protein intake to build muscle.  At the end of the study, there was no significance 
between BMI and protein, suggesting that there is no correlation at all.  In other words, there was 
no change in the data and no way to determine if PEW among the patients is present due to the 
unchanged BMI values compared to nutrient (energy and protein) values at the end of the study.  
There were additional results pertaining to BMI’s relationships.  During the correlation 
tests, BMI negatively correlated with HDL cholesterol (table 5.7) suggesting that high BMI 
entails low HDL cholesterol, which agrees with previously established literature [33].  Other 
notable observations, which agreed with current literature, were the positive correlation between 
BMI and triglycerides, positive correlation between total cholesterol and triglycerides, negative 
correlation between HDL cholesterol and triglycerides, and the positive correlation between LDL 
cholesterol and total cholesterol [33]. 
 The biochemical profiles of serum albumin and IL-6 were observed to indicate possible 
changes in nutritional and inflammatory status [9], respectively.  Any decrease in serum albumin 
or increase in IL-6 could raise mortality risk [5], [3], [9].  It is reported that no changes were 
detected in serum albumin or IL-6.  Most patients remained in the <3.8 g/dL and 3.9-4.2 g/dL 
ranges at both time points.  There was not any relationship between serum albumin and the 
individual nutrients when correlation tests were run.  Moreover, IL-6 values were insignificant at  
an average of 6.9 pg/mL (7.9 pg/mL for placebo and 5.8 pg/mL for TRF).  These values did not 
change at week 16 indicating no effect on inflammatory markers.  There was some slight positive 
correlation with food-sourced T3, however, the study was to determine the effect of total T3 
administered to the patients and therefore this was disregarded. At the end of the study there was 
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no significant change due to any of the nutrients.  This may not be enough to state whether or not 
mortality risk has been affected in favor of lessening the risk or that there is a basis for IL-6 
induced protein energy wasting [8]. 
 One of the main points the study was trying to investigate was whether there was a 
presence of malnutrition detected in the nutrient intake of the patients.  Interestingly, since the 
nutrient data was recorded at two time points starting at week zero and then week 16, the 
numbers should have indicated malnutrition based on the comparison with the United States 
Renal Data System (USRDS) data or other cohort hemodialysis studies.   
The values for total calories consumed per kilogram of body weight were 27 kcal/kg 
body weight versus USRDS recommended 35 kcal/kg body weight.  One can see that these 
values fell below the USRDS recommendations.  This remained unchanged at the end of the 
study as well.  It does not appear that the T3 supplements have had an effect on nutrient intake or 
appetite considering energy intake has remained the same at both time points.  Moreover, the 
numbers may also appear lower; p-values were not significant, and therefore no significant 
difference existed between the caloric intakes between the two groups.  These values that 
represent the study population are inadequate, meaning that population size or compliance may 
have played a factor in the t-test results.  
After analyzing the protein intake, it appears that there was no change in intake over the 
course of the 16-week study.  It started off approximately 18-19% of the meals, but remained the 
same (from an overall of 94 ± 52 g to 90 ± 51 g) at the end of the study.  After analyzing the 
consumption patterns, it increased along with the consumption of other nutrients such as 
carbohydrates, fat, cholesterol and MUFA. There was no significant difference between the 
groups at both time points and the protein consumed by body weight also was unchanged.  NKF 
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KDOQI guidelines recommend hemodialysis patients consume more than 1.2 g/kg body wt, 
which only the placebo group (1.24 ± 0.77 g/kg body wt) has at both time points.  The patients in 
the TRF groups were consuming less than that recommended amount and are at risk for protein-
calorie malnutrition and hypoalbuminemia [10].  It was recommended that HD patients consume 
protein that comprises ≥15% of the diet, which the study population appears to have achieved.  
However, the total energy intake does not reflect the individual protein intake.  There may have 
been inaccuracies with the diet recall, issues with the population size, or non-significance of the 
values may have produced these results. 
Carbohydrate was the nutrient that comprised 42-45% of the diet.  As this was between 
baseline and week 16, not much difference between the.  It should be about 50-60% of the diet 
[31], which the study population was not able to meet.  This could also explain why the caloric 
density intake is below the KDOQI recommended 35 g/kg body weight.  Average fiber intake 
was around 13 mg at baseline and week 16.  Both groups did not meet the recommended intake 
of an estimated 20-25 mg [31].  As suggested by previous literature, the problem with a low fiber 
intake is that it can negatively affect lipid levels [31].  One interesting point that appears to stand 
out is the fact that baseline fiber intake decreased as cholesterol intake increased after analyzing 
the correlations in table 5.8.  This suggests that the inverse relationship could be explained by the 
lipid lowering effect fiber has during consumption that is suggested in previous literature.  
However, cholesterol intake was higher than expectations thereby suggesting the opposite and 
setting the patients up for heart disease.  The food choices many patients made were comprised 
of refined or simple carbohydrates instead of complex variety such as fiber.   
Lipid intake in this study population reflects a diet that promotes an increased heart 
disease risk.  Cholesterol intake of the patients exceeded the American Heart Association (AHA) 
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recommendation of <300 mg/day.    This intake may subject the patients to hyperlipidemia 
according to the AHA, and given their current health state, the risk for mortality is greater.  The 
high cholesterol intake is mainly due to the frequency of egg consumption as seen on the diet 
recalls.  When it comes to Total Fat intake, the patients consumed a diet that is comprised of 36-
40% of it.  Moreover, Saturated fat comprised 14% of the diet and unsaturated fat was about 
22% (MUFA-14%, PUFA-8%) at baseline.  At week 16, the diets were 13% saturated fat and 
19% unsaturated fat (MUFA-12%, PUFA-7%).  Interestingly, MUFA and Saturated fat had a 
tendency to be significant since the p-value was between 0.05 and 0.1.  The values may have a 
tendency to reflect the intake in both groups and a slight difference.  However, there may have 
been factors that caused the statistical analysis test to come up non-significant (e.g. inaccurate 
diet recall), which is why certain nutrients that are not accounted for in the total caloric intake.  
According to AHA, the study population did not meet their recommendations.  The 
patients exceeded the recommended intakes for total fat and saturated fat [31] thereby increasing 
their risk for heart disease.  This could be viewed in the correlation studies (see table 5.5) on how 
total fat and saturated fat positively correlated with Total Calories.  This means that the intake of 
both increased while there was an increase of Total calories. 
  Along with macronutrient intake, micronutrients were tracked as some are held in high 
importance to the ESRD population (e.g. sodium, potassium, phosphorous, Vitamin A, Vitamin 
C).  The majority of micronutrient consumption in the study did not change from baseline to 
week 16.  Towards the end of the study, there was no significant difference between the groups.   
When sodium intake was detected at averages around 3000 mg per day, it exceeded the 
recommendations of <2000 mg [31]. It appears to be cumbersome for the patients since sources 
of sodium are primarily dietary-based or found in dialysate [34]. Potassium intake remained at 
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around 2000 mg at baseline and week 16, therefore exhibiting no change.  Both groups’ values 
had no significant differences.  When it was compared to other dialysis studies, it exceeds their 
recommended ranges as well [31].  Tracking its behavior with other nutrients, potassium 
increased with increases in Total Calories, sodium intake (week 16 only), vitamin C, calcium, 
iron, phosphorous, and fiber.  Sodium intake increased along with the following nutrients (table 
5.6): Total Calories and Phosphorous at both time points, and with Potassium, Calcium, Iron, and 
Fiber at week 16.  Based on these observations, the foods frequently consumed contained these 
common nutrients.   Since t-tests did not prove significance, it may explain why these 
micronutrient intakes are not consistent with caloric intake.  Moreover, the results of other 
studies have shown high potassium intake associated with increased death or survival hazards 
[35].  It can be in part due to issues like hyperkalemia caused arrhythmia [31].  High sodium 
intake concurrent with hypertension in normal population is more problematic in the kidney 
disease population since CVD is associated with complications leading to greater mortality [34].  
Based on these numbers, the study population managed to keep potassium intake under control.  
However, the validity of the results may be questionable considering the study limitations which 
is viewed in the t-tests. 
Phosphorous intake is of high importance to the ESRD population.  Patients are 
encouraged to consume low amounts through diet and take binders since it is also affects calcium 
levels within the body [36].  Other important attributes in the CKD population is the awareness 
of soft tissue calcification associated with CVD risk [36].  Baseline and week 16 intake was 
between 950-1200 mg.  The t-tests proved that there was no significant difference between the 
groups at both time points.  Phosphorous did correlate with the majority of micronutrients, 
including dietary-based T3 at baseline only.  The reason for these numbers is that various foods 
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consumed by the patients contained large amounts of phosphorous (e.g. beef, chicken, processed 
foods, condensed soups).  These foods have common nutrients such as phosphorous, which may 
be why it had correlated with the intake of other micronutrients.  The intake of phosphorous have 
been above recommendations at baseline and below them at week 16 [31].  Because there was no 
significance, it would be difficult to make that observation on their diet behavior being affected 
by their state of health.   
The vitamins that were analyzed hold relevancy to the dialysis population.  Some of these 
micronutrients are fat soluble (e.g. Vitamin A, E) and water soluble (e.g. Vitamin C).  The water 
soluble vitamins are easily depleted during dialysis [37].  The vitamins that had been analyzed 
are all antioxidants and knowing the intakes of each would provide insight into a patient’s 
antioxidant status.  
Average intake of Vitamin C at baseline and week 16 was about 80-110 mg, which 
happens to be within the recommended amount of 60-100 mg [31].  This may not be enough due 
to potential reduction in levels during the dialysis process [37], and therefore requires 
supplementation.  Vitamin C is protective for heart disease because of its antioxidant attributes.  
Even though it may appear that Vitamin C had a tendency to be significant at baseline, it is 
important to note that the time of this diet recall was taken before supplementation and should 
not be different at all.  Week 16 values had no significant difference between the groups meaning 
that the unchanged values carried over throughout the study.   
Vitamin A is another form of anti-oxidant whose levels did not necessarily change in the 
16 weeks.  The average intake at baseline was around 7400 mg but there was no significant 
difference between the two groups.  At week 16, even though intake was about 6000 mg, there 
still was no difference between the groups.  One other interesting point is that one of the patients 
	  	  
54	  
consumed 16 ounces of liver, rich in vitamin A, which explains the unusually high standard 
deviation in the baseline TRF group.  Based on this study population, it appears as shown in 
previous studies that excessive intake of vitamin A does not benefit patients since it has a pro-
oxidant effect [31].   
Some of these vitamins appear to surpass the recommendations, however, no significance 
may question the validity of their values due to the study’s limitations and how they may not 
match with the values concurrent with a dialysis population.  This may also explain, for example, 
why Vitamin C correlated with micronutrients at certain time points, or why Vitamin A 
correlated with few nutrients in question.  Vitamin A’s intakes were unusually high given that 
overall energy intake was low.  Again, it would be difficult to argue this assumption considering 
these values were not significant.   
The final vitamin, E, has been taken into account due to antioxidant capabilities.  Both 
tocopherols and T3 were tracked.  Tocopherol intake was around 10 mg at baseline and 6 mg at 
week 16.  There were no significant differences at either time and the data tables also show that 
there was not any variation based on those t-test evaluations (which also applied to previous 
nutrient evaluations).  Only baseline values have met recommended levels, however, there is not 
enough justification for the use of tocopherols in the prevention of coronary artery disease [31] 
according to the AHA.  When the study population’s T3 intake was analyzed, primarily dietary 
based at baseline, was marginal since they are between 2-3 mg with no significant difference.  At 
week 16, one of the groups received supplementation in addition to dietary-based T3 and that is 
why there was a large variation of 2-182 mg, which may have explained the significance 
between the two groups.  It is important to note that tocopherols and T3 share the same transport 
protein when in circulation in the body [26] for which tocopherols have a higher affinity.  
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Unfortunately, there was not enough evidence based on average intakes and non-significance to 
detect a change in the intake of other nutrients due to overlying causes as aforementioned.  Also, 
the intake at week 16 is primarily sourced from supplements for the TRF group.  Other notable 
inquiries in the results were that T3 and dietary cholesterol at baseline had a negative correlation, 
which means that T3 intake involved a decrease in cholesterol intake.  This may be due to T3 
rich foods being more prevalent in reference to cholesterol rich foods within the diet.  T3 also 
increased with saturated fat at week 16, meaning that saturated fat-rich foods may also have 
either contained T3s or were eaten frequently with separate T3-containing foods.  One interesting 
point would be the positive correlation between T3 intake and IL-6 at baseline only.  It may be 
that the patients consuming T3-rich foods have a higher incidence of IL-6.  Il-6 being a 
biochemical marker for inflammation should be decreased after supplementation, however, this 
did not happen based on no correlation with T3 intake at week 16.  It may be easy to rule out 
T3’s ineffectiveness, but the non-significance in baseline values for other nutrients may require 
more information or testing. 
  As one can observe here, the study population has less than required energy and protein 
intake, whereas the micronutrient intake varies.  Some are below while certain micronutrients are 
above recommended levels.  This may also explain why the study population’s diet was not 
consistent with heart healthy as compared to similar dialysis studies [31]: fat and carbohydrate 
intake was not optimal.  In addition to the macronutrients, sodium levels were high enough to put 
the patients in a hypertensive state.  Basically, no discernible effect was detected in terms of 
nutrient intake after supplement treatment.  Additionally, it could be due to the quality of 
analysis based on t-tests or correlations that make no detectable pattern.  It would be difficult to 
identify signs of malnutrition since the week 16 data did not exhibit significant difference 
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between the two groups.    Perhaps it is advisable to disregard the fact that T3 may have played a 
role in nutrient intake behavior since almost every nutrient average had no significant difference 
between the groups at the conclusion of the study. 
Other notable issues that arose during the data analysis of the food intake were a 
possibility of inconsistencies with the actual diet recalls.  It could be that the diet recalls may 
contain some inaccuracy since they are solely based on the patients’ memory.  Portion size may 
have been exaggerated or that estimation of servings during transcription into the Nutritionist Pro 
software may not be accurate.  This could have had some influence on the patient’s diet 
composition.  Moreover, many foods recorded from patients were not found in the Nutritionist 
Pro’s central database and alternatives were used in place of some food items.   
The data that was collected on T3 intake through food was pooled from external 
resources and their accuracy is questionable.  In other words, the data analysis run by SPSS that 
gave non-significant results could have been affected by the diet recall or transcription 
inaccuracy.  This can affect the t-tests and correlations, leading to the conclusion that there was 
no change in nutrient data detected when T3 supplements were administered.  Other notable 
inquiries would be study limitations.  Diet recalls were limited to two times and only at the start 
and conclusion of the study.  
 One cannot conclude that T3s are ineffective against stabilizing the complications 
attributed to ESRD.  One observation showed total calories correlated with some nutrients at 
week zero but less at week 16.  This produces mixed results and would not be easy to provide 
any direct conclusion that T3s had any effect.  A future study may want to test with an increased 
dose of T3 to compare with previous results and how nutritional behavior may react with a larger 
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dose so that optimal levels can be investigated.  That, along with a larger population size, would 
entail a smaller margin of error.  
As one would address the study’s limitations, the logistical issues concerning data 
collection would require the researchers to take a more detailed account.  Addressing issues with 
the effectiveness of a 24-hour diet recall could justify providing patients with their own food 
diaries so that they can record their meals immediately after consumption.  This would ensure 
more accurate reporting of portion size.  To address the discrepancy between energy and nutrient 
intake, it may be beneficial for patients to receive more extensive nutritional counseling, in order 
to ensure compliance with recommended intakes. 
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Kidney disease is defined by a loss of kidney function over time [1].  It is expressed in 
terms of glomerular filtration rate at five stages calculated by the MDRD formula [5].  The fifth 
stage (<15 mL/min/1.73m2) is designed as end stage renal disease requiring renal replacement 
therapy in the form of hemodialysis [5].  This requires the use of an artificial kidney (dialyzer) to 
filter out by-products from the blood for excretion [8].   The issue arises when toxin 
accumulation due to decreased renal function, dialytic factors such as incompatible dialyzer 
membranes reacting with blood, and co-morbid conditions such as infection or diabetes mellitus 
[3].  This increases inflammation within the body, leading to a negative nutrient/energy balance, 
resulting in a loss of body mass thereby increasing the mortality risk [10].  Tocotrienols (T3), a 
more potent and underutilized form of Vitamin E, are being administered to attenuate this 
increase in inflammation via supplementation in addition to food intake.  A cohort of 
hemodialysis patients was analyzed in order to study this issue.  The nutritional status was 
assessed utilizing three measures: examining nutrient intake profiles (while supplementation was 
taken into consideration), obtaining anthropometric findings of body mass index, and analyzing 
biochemical profiles of serum albumin and pro-inflammatory markers (i.e. IL-6).  This data was 
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obtained via a randomized, double blind, placebo-controlled study of 81 dialysis patients.  At 
two times over the course of 16 weeks, blood collection for serum albumin and inflammatory 
markers was analyzed and dietary intake was assessed using 24-hour diet recalls and Nutritionist 
Pro software.  Statistical analyses of paired t-tests and correlation studies revealed no significant 
differences between the two groups later showing no noticeable effect of T3 supplementation.  
Reasoning may be multifactorial such as underestimation of food intake, transcription of diet 
recalls may not be truly representative, or T3 supplements may not have had an effect on the 
nutritional statuses.  It may be beneficial for patients to receive more extensive nutritional 
counseling as opposed to nutritional supplementation to ensure compliancy with recommended 
intakes. 
